Medtronic

(redirected from Medtronic Diabetes)

Medtronic

A major manufacturer of pacemakers, defibrillators and other cardiac devices.

Medtronic

Cardiology A major manufacturer of pacemakers, defibrillators, and other cardiac devices
References in periodicals archive ?
One investigator receives research support from Medtronic Diabetes and is a consultant for Abbott Diabetes Care, Bigfoot Biomedical, Adocia, and Roche.
He has more than 12 years of experience as an executive sales representative and territory manager with Eli Lilly Pharmaceuticals and Medtronic Diabetes medical devices.
"Our Medtronic Diabetes team will work as quickly as possible to complete all exchanges to the new and enhanced set and fully support our customers throughout this process."
The problem is that the HbA1c is "woefully inadequate," said Robert Vigersky, MD, the medical director of Medtronic Diabetes and president of the Endocrine Society in 2009-2010.
People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.
AmEx/ OPEN, Medtronic Diabetes, Unilever, IBM, and Clubcorp, among others, are creating these new advisory boards to:
Medtronic spokesman Steve Sabicer explained, "The business model is a little different for Medtronic Diabetes from other divisions because of the interaction with the patient; the other divisions communicate directly with the physician and the hospital."
IBM : Solutions Big Data for the government of Africa Ebola Humanitarian Efforts, insurance identification efforts of fraud in the Department of Health and Human Services North Carolina, the Hospital de Clinicas in Seattle, as well as alliances industry develop new solutions for Medtronic diabetes and self - care applications for smart devices Apple technology.
The problem is that the [HbA.sub.1c] is "woefully inadequate," noted Robert Vigersky, MD, the medical director of Medtronic Diabetes and president of the Endocrine Society in 20092010.
Scherr reported having no financial disclosures relevant to the current study and receiving product support from Medtronic Diabetes for investigator-initiated studies.
Under the deal, Medtronic will fund and provide its drug-device expertise as Nile executes on its Phase I study to assess the pharmacokinetics and phamacodynamics of cenderitide delivered through Medtronic diabetes pump technology.